When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all [1]

Clinical Infectious Diseases

Volumn 44, Issue 5, 2007, Pages 757-760

  Miceli, Marisa H ^a   Anaissie, Elias J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; GALACTOMANNAN; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; INFLAMMATION; LETTER; LUNG INFILTRATE; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; BETA-GLUCANS; FUNGAL PROTEINS; HUMANS; MANNANS; PEPTIDES, CYCLIC;

EID: 33847034417     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511080     Document Type: Letter

References (14)

1. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43:e23-5.
2. Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41:e9-14.
3. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-43.
4. Petraitis V, Petriatiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
5. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
6. Petraitis V, Petriatiene R, Hope W, et al. Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergilllosis [abstract M-882]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2006.
7. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg [A. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57:732-40.
8. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53:131-9.
9. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56:594-7.
10. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50:422-7.
11. Luther K, Torosantucci A, Brakhage AA, Heesemann J, Ebel F. Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2. Cell Microbiol 2006; 9:368-81.
12. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomographyscans in patients with neutropenia. J Clin Oncol 2001; 19:253-9.
13. Takuma T, Okada K, Uchida Y, Yamagata Am, Sawae Y. Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia. J Intern Med 2002; 252:173-7.
14. Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999; 29:453-7.